A study is presented on improving the absorption of the PbS colloidal quantum dot (CQD) films using plasmonic scattering. Unlike previous methods that include high temperature annealing, an ...integrated circuits (IC) compatible method of introducing colloidal gold nanoparticles to PbS film during the spin deposition process is developed. The devices are composed of eight layers of PbS and gold nanoparticles are spin cast after the fourth layer that places them in the middle, sandwiched between PbS films in order to avoid electrical shorts between the fingers. Two different solutions of gold nanoparticles in citrate, 0.1% and 0.01%, are used to fabricate two different devices. Introducing 0.01% Au nanoparticles in PbS film increases the responsivity 2.6-fold, whereas introducing 0.1% Au nanoparticles results in a 6.5-fold increase in responsivity.
A study is presented on improving the absorption of the PbS colloidal quantum dot films using plasmonic scattering. Unlike previous methods that include high temperature annealing, an integrated ...circuits compatible method of introducing colloidal gold nanoparticles to PbS film during the spin deposition process is developed. The devices are composed of eight layers of PbS and gold nanoparticles are spin casted after the fourth layer that places them in the middle, sandwiched between PbS films in order to avoid electrical shorts between the fingers. Two different solutions of gold nanoparticles in citrate, 0.1% and 0.01%, are used to fabricate two different devices. Introducing 0.01% Au nanoparticles in PbS film increases the responsivity by 2.6-fold, whereas introducing 0.1% Au nanoparticles results in a 6.5-fold increase in responsivity.
This paper presents a biosensor implementation for the detection of protein molecules using specific antibodies. Affinity sensors allow the detection and quantification of target molecules in complex ...mixtures by affinity-based interactions. Immobilized antibody molecules are the probes that bind to specific protein molecules (targets) in biological fluids. In this study, interdigitated electrodes in the form of capacitance on glass slide were designed/simulated and used to measure the changes in the dielectric properties of the interdigated capacitances.
Sabanci University Nanotechnology Research and Application Center (SUNUM) is developed with approximately 30 M and started its operations in June 2011. The center provides valuable additional ...capabilities to the existing research infrastructure of the Faculty of Engineering and Natural Sciences of Sabanci University. The high-tech facility is designed to support cutting-edge scientific and technological research related to nanotechnologies including advanced materials, nano-biotechnology, nano-medicine, nano-electronics, micro-nanofluidics, nanomechanics, nano-optics, micromachining, micro and nano-systems and alternative energy sources.
This paper presents the design of an UWB SiGe BiCMOS mixer block for direct-conversion type transceiver architectures which optimized for WLAN applications at a frequency of 5 GHz using 0.35 mum SiGe ...BiCMOS technology. High gain, low noise figure (NF) and low power dissipation are the main considerations for optimizations. The simulations are performed using Cadence reg SpectreRF environment. The simulation results show a gain of 11 dB, Noise Figure of 5 dB and 1-dB compression point of -14 dBm. The circuit consumes only 15 mW under 2.5 V supply voltage
In this paper, design and realization of a parallel plate dual gap MEM-Varactor based -Gm LC voltage controlled oscillator (VCO) is presented. The VCO is implemented with AMS 0.35 mum-SiGe BiCMOS ...process that includes high-speed SiGe heterojunction bipolar transistors (HBTs). MEM-Varactor is fabricated in Sabanci University's cleanroom and includes six layers and five mask steps. MEM-varactor and VCO is integrated on a FR4 substrate using wire bonder. With the actuation voltage of 0 to 10 V, 70 MHz tuning range is measured from MEM-varactor integrated VCO that is in the range 7.72 GHz to 7.80 GHz. Fundamental frequency output power changes between -2 dBm and 0 dBm, without the losses depending on the tuning voltage.
In this paper, design and realization of a parallel plate dual gap MEM-Varactor based -G m LC voltage controlled oscillator (VCO) is presented. The VCO is implemented with AMS 0.35 mum-SiGe BiCMOS ...process that includes high-speed SiGe Heterojunction Bipolar Transistors (HBTs). MEM- Varactor is fabricated in Sabanci University's cleanroom and includes six layers and five mask steps. MEM-Varactor and VCO is integrated on a FR4 substrate using wire bonder. With the actuation voltage of 0 to 10V, 70 MHz tuning range is measured from MEM-Varactor integrated VCO that is in the range 7.72 GHz to 7.80 GHz. Fundamental frequency output power changes between -2 dBm and 0 dBm, without the losses depending on the tuning voltage.
Background
Ado-trastuzumab emtansine is an antibody-drug conjugate that combines the cytotoxic activity of emtansine with human epidermal growth factor receptor 2-targeted antitumor features of ...trastuzumab.
Objective
We conducted a study of metastatic breast cancer patients treated with trastuzumab emtansine. By evaluating progression-free survival, overall survival, and response rates, we aimed to find prognostic factors of trastuzumab emtansine treatment.
Methods
Our study is a single-center, retrospective, observational study. We have clinical data from 78 patients treated with trastuzumab emtansine for metastatic breast cancer, from May 2016 through May 2019, at Kartal Dr Lutfi Kirdar Education and Research Hospital, Medical Oncology Department. Our objective is to assess the survival and response rates in trastuzumab emtansine-treated individuals and the factors associated with survival. The factors we analyzed were cancer antigen 15-3 sensitivity, Eastern Cooperative Oncology Group-Performance Status, presence or absence of visceral metastases, presence or absence of cranial metastases, and treatment-associated thrombocytopenia.
Results
Among 78 patients, median progression-free survival was 7.8 months, and overall survival was 21.1 months. Twenty of the patients had an objective tumor response. The results showed that trastuzumab emtansine was tolerable with a manageable safety profile and consistent with the results of the previous literature. Mostly seen adverse events were anemia, thrombocytopenia, fatigue, and increased levels of alkaline phosphatase. Patients with Eastern Cooperative Oncology Group-Performance Status = 2 had worse progression-free survival and overall survival compared to ones with Eastern Cooperative Oncology Group-Performance Status < 2; progression-free survival and overall survival are worse in cancer antigen 15-3-sensitive breast cancer patients. According to our findings, treatment-associated thrombocytopenia was a significant prognostic factor for survival. Patients with thrombocytopenia had 12 months progression-free survival, whereas patients without thrombocytopenia had only 4.1 months progression-free survival. In like manner, overall survival was much better in the thrombocytopenia-experienced patients as 29.5 versus 11.8 months.
Conclusions
Trastuzumab emtansine prolongs progression-free survival and overall survival with a manageable safety profile. Thrombocytopenia, Eastern Cooperative Oncology Group-Performance Status, and cancer antigen 15-3 are correlated with progression-free survival and/or overall survival.
Breast cancer (BC) remains a significant health concern, particularly in advanced stages where the prognosis is poor. The combination of endocrine therapy (ET) with cyclin-dependent kinase 4/6 ...inhibitors (CDK4/6i) has improved outcomes for advanced BC (aBC) patients. However, resistance to CDK4/6i remains a challenge, with no validated biomarkers to predict response. The receptor activator of the nuclear factor-kB (RANK) pathway has emerged as a key player in aBC, particularly in luminal BC. RANK overexpression has been associated with aggressive phenotypes and resistance to therapy. In view of these findings, we proceeded to investigate the potential involvement of the RANK pathway in luminal BC resistance to CDK4/6i. The objective was to evaluate the effectiveness of denosumab in increasing overall survival (OS) and progression-free survival (PFS).BACKGROUND AND OBJECTIVEBreast cancer (BC) remains a significant health concern, particularly in advanced stages where the prognosis is poor. The combination of endocrine therapy (ET) with cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) has improved outcomes for advanced BC (aBC) patients. However, resistance to CDK4/6i remains a challenge, with no validated biomarkers to predict response. The receptor activator of the nuclear factor-kB (RANK) pathway has emerged as a key player in aBC, particularly in luminal BC. RANK overexpression has been associated with aggressive phenotypes and resistance to therapy. In view of these findings, we proceeded to investigate the potential involvement of the RANK pathway in luminal BC resistance to CDK4/6i. The objective was to evaluate the effectiveness of denosumab in increasing overall survival (OS) and progression-free survival (PFS).In this retrospective analysis, 158 BC patients with bone metastases were included. Patients with human epidermal growth factor receptor-2 (HER2)-negative and hormone receptor-positive BC who received palbociclib or ribociclib in addition to antiresorptive medication were included. Patients received either denosumab or zoledronic acid (ZA) therapy. The primary endpoint was OS, with PFS as a secondary endpoint.METHODSIn this retrospective analysis, 158 BC patients with bone metastases were included. Patients with human epidermal growth factor receptor-2 (HER2)-negative and hormone receptor-positive BC who received palbociclib or ribociclib in addition to antiresorptive medication were included. Patients received either denosumab or zoledronic acid (ZA) therapy. The primary endpoint was OS, with PFS as a secondary endpoint.Although the PFS and OS of denosumab were better than ZA in this study, it did not show a significant difference between the two drugs. Meanwhile, mOS was not achievable in patients in the denosumab group, while it was 34.1 months in patients in the ZA group. The hazard ratio (HR) showed a significant improvement for the denosumab group in patients under 60 of age (HR: 0.33, p<0.01), patients with a score of 1 HER2 overexpression (HR: 0.09, p=0.01), and patients with resistant endocrine (HR: 0.42, p=0.02) compared to ZA.RESULTSAlthough the PFS and OS of denosumab were better than ZA in this study, it did not show a significant difference between the two drugs. Meanwhile, mOS was not achievable in patients in the denosumab group, while it was 34.1 months in patients in the ZA group. The hazard ratio (HR) showed a significant improvement for the denosumab group in patients under 60 of age (HR: 0.33, p<0.01), patients with a score of 1 HER2 overexpression (HR: 0.09, p=0.01), and patients with resistant endocrine (HR: 0.42, p=0.02) compared to ZA.This study highlights the potential clinical relevance of the RANK pathway in BC treatment, and our findings suggest that denosumab may offer significant benefits in terms of PFS and OS for certain subgroups, particularly those with HER2 scores of 1, patients under 60, and those with endocrine-resistant BC. In conclusion, considering that RANK pathway status may be a predictive biomarker for CDK4/6i treatment and may cause treatment resistance, our results demonstrate the clinical relevance of the combination of CDK4/6i + ET with RANKL inhibition.CONCLUSIONThis study highlights the potential clinical relevance of the RANK pathway in BC treatment, and our findings suggest that denosumab may offer significant benefits in terms of PFS and OS for certain subgroups, particularly those with HER2 scores of 1, patients under 60, and those with endocrine-resistant BC. In conclusion, considering that RANK pathway status may be a predictive biomarker for CDK4/6i treatment and may cause treatment resistance, our results demonstrate the clinical relevance of the combination of CDK4/6i + ET with RANKL inhibition.
Abstract Objectives Following the encouraging results of several registries and trials, transcatheter aortic valve implantation (TAVI) has been recognized as a valid option in patients with severe ...aortic stenosis deemed at high or prohibitive risk for surgical treatment. Good procedural success and good clinical outcomes have been showed and very limited data exist on TAVI in the setting of a preexisting mitral prosthesis regarding the technique, potential complications, and outcomes. Methods Here, we report six cases of transfemoral TAVI with a self-expanding bioprosthesis (CoreValve; Medtronic, Inc) in patients who had previously undergone mitral valve replacement. Preprocedural, intraprocedural ve postprocedural outcome and data were analyzed and a brief literature review is also presented. Results and conclusion Our experiences show that transfemoral CoreValve implantation can be performed successfully in patients with mechanical and bioprosthetic mitral valves.
